IMPACT Therapeutics, Inc (HKG:7630)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
11.60
-1.63 (-12.32%)
Aug 3, 2026, 4:08 PM HKT
Market Cap3.65B
Revenue (ttm)42.57M +14.0%
Net Income-329.31M
EPS-1.44
Shares Out 276.17M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume569,680
Open13.23
Previous Close13.23
Day's Range11.48 - 13.23
52-Week Range10.31 - 47.98
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About IMPACT Therapeutics

IMPACT Therapeutics, Inc., a biotechnology company, researches and develops synthetic lethality (SL)-based precision anti-cancer therapies in China and internationally. The company offers a product, (IMP4297) Senaparib, a PARP1/2 inhibitor that is used for 1L maintenance therapy for ovarian cancer (OC). Its pipeline products includes IMP1734, a next-generation poly (ADP-ribose) polymerase (PARP)1 selective inhibitor evaluated as monotherapy, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; IMP9064, an ataxia tel... [Read more]

Sector Healthcare
Founded 2009
Employees 58
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 7630
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements